BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15598929)

  • 1. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens.
    Amato RJ
    Ann Oncol; 2005 Jan; 16(1):7-15. PubMed ID: 15598929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted anti-cancer therapies for renal cancer.
    Amato RJ; Jac J
    Drugs; 2006; 66(17):2161-71. PubMed ID: 17137401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide therapy for renal cell carcinoma.
    Amato RJ
    Crit Rev Oncol Hematol; 2003 Jun; 46 Suppl():S59-65. PubMed ID: 12850528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving role of novel targeted agents in renal cell carcinoma.
    Hutson TE; Figlin RA
    Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecularly targeted therapy for gastrointestinal cancer.
    Wiedmann MW; Caca K
    Curr Cancer Drug Targets; 2005 May; 5(3):171-93. PubMed ID: 15892618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In focus: bevacizumab for renal cell carcinoma.
    Clin Adv Hematol Oncol; 2005 Jan; 3(1):68-9. PubMed ID: 16166971
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune Checkpoint Therapy in Renal Cell Carcinoma.
    Lee CH; Motzer RJ
    Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-VEGF therapy for renal cell carcinoma.
    Escudier B
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):530-1. PubMed ID: 17679926
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-angiogenic therapy in renal cell cancer.
    Srinivasan R; Armstrong AJ; Dahut W; George DJ
    BJU Int; 2007 May; 99(5 Pt B):1296-300. PubMed ID: 17441927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial.
    Amato RJ; Jac J; Hernandez-McClain J
    Anticancer Drugs; 2008 Jun; 19(5):527-33. PubMed ID: 18418219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted agents for the treatment of advanced renal cell carcinoma.
    Staehler M; Rohrmann K; Haseke N; Stief CG; Siebels M
    Curr Drug Targets; 2005 Nov; 6(7):835-46. PubMed ID: 16305462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New targets and drugs for treatment of advanced renal cell carcinoma].
    Rohde D
    Aktuelle Urol; 2005 Apr; 36(2):125-30. PubMed ID: 15902572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New treatment approaches for metastatic renal cell carcinoma.
    Nanus DM
    Curr Oncol Rep; 2000 Sep; 2(5):417-22. PubMed ID: 11122873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor necrosis factor (TNF-a) antibodies in the treatment of renal cell cancer.
    Maisey N
    Cancer Invest; 2007; 25(7):589-93. PubMed ID: 17852116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
    Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapeutic options in metastatic renal cancer - review and post ASCO 2007 update.
    Kruck S; Kuczyk MA; Gakis G; Kramer MW; Stenzl A; Merseburger AS
    Rev Recent Clin Trials; 2008 Sep; 3(3):212-6. PubMed ID: 18782079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC).
    Atkins MB; Philips GK
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):243-54. PubMed ID: 27539246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.